Newsletter | March 25, 2025

03.25.25 -- How To Build Resilience Amid Dynamic Biopharma Vendor Relationships

SPONSOR

The debate rages on. While the automation that enables continuous processing gets a lot of hype, there are plenty of dyed-in-the-wool biopharma pros who contend that process optimization and intensification yield comparable benefits, without requiring the capital-intensive process overhaul that continuous demands. Join Bioprocess Online Live for a virtual deep dive into the scalability, sustainability, and capital implications of the continuous-versus-optimized debate. Registration is free thanks to the support of Cytiva.

FOCUS ON OUTSOURCING

How To Build Resilience Amid Dynamic Biopharma Vendor Relationships

The key to effective vendor management lies in understanding how relationships derail in the first place. Here are some common reasons and tips on how to avoid them.

Gliding Towards De-Risked Combination Product Development

Learn about the critical role plunger stoppers play in determining a combination drug product's exposure to extractables and leachables.

A Playbook For Accelerating Success While Maintaining Quality

From the digital infrastructure needed to enable a collaborative approach, to the quality systems and analytical methods, effective tech transfer relies on the careful consideration of a variety of factors.

Plan Your CDMO Search On A Foundation For Long-Term Success

Capacity constraints typically are accompanied by other challenges, including missed timelines, defect rates, and overall decreased satisfaction with pharma companies’ bioprocessing CDMOs.

Integrated Services For Cell Line Preparation And Storage

Explore a comprehensive suite of services for the manufacture, characterization, and storage of cell banks as well as the advantages of working with an experienced partner.

Enhancing The Upstream Performance Of AAV Vector Manufacturing

Unlock the potential of AAV manufacturing by leveraging data-driven insights and the advanced Pro10™ platform to optimize processes, enhance productivity, and drive innovation in cell and gene therapy.

Leveraging Digital Solutions To Reshape The CDMO Experience

CDMO customers consistently state that access to near real-time data is crucial to their ability to make timely, informed decisions, especially during early development.

OUTSOURCING SOLUTIONS

Factors Which Impact mAb Process Scale-Up - Cytiva

Capacity Update January 2025: Cell & Gene Therapy - Aldevron

A New Player With A Long History - Andelyn Biosciences

Capacity Update January 2025: Large Molecule Development - Mabion

Biologics Discovery, Development, And Manufacturing - Curia

Connect With Bioprocess Online: